22Nov/17
Collaboration to Evaluate Combination of Nivolumab + Brentuximab Vedotin in Phase III Trial in Relapsed Hodgkin Lymphoma Expanded
“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…